Abstract
Inactivation of the p16 gene is believed to contribute to the tumorigenic process of several neoplasms, including head and neck tumours. In the present study, DNA samples from paired tumour and adjacent normal tissue from 47 patients with squamous cell carcinoma of the head and neck were investigated for the occurrence of p16 genetic alterations. Single-strand conformation polymorphism and direct DNA sequence analysis led to the identification of p16 mutations in six cases (13%). Southern blot analysis showed that homozygous deletion is a rare event in the group of tumours analysed. Loss of heterozygosity (LOH) analysis was performed by polymerase chain reaction (PCR) using two microsatellite markers (IFNA and D9S171) from the 9p21 region. Taking into account only the informative cases, 17 of 32 tumours (53%) showed LOH for at least one of the markers analysed. The methylation status of the CpG sites in the exon 1 of the p16 gene was analysed using methylation-sensitive restriction enzymes and PCR amplification. Hypermethylation was observed in 22 (47%) of the head and neck tumours analysed. In our series of head and neck tumours, evidence for inactivation of both p16 alleles was observed in 13 cases with hypermethylation and LOH, two cases with hypermethylation and mutation, four cases with mutation and LOH and one case with homozygous deletion. These findings provide further evidence that genetic alterations, especially hypermethylation and LOH, leading to the inactivation of the p16 tumour suppressor gene are common in primary head and neck tumours.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arap, W, Knudsen, E, Sewell, DA, Sidransky, D, Wang, JY, Huang, HJ & Cavenee, WK (1997) Functional analysis of wild type and malignant glioma derived CDKN2Abeta alleles: evidence for an Rb-independent growth supressive pathway. Oncogene 15: 2013–2020
Cairns, P, Mao, L, Merlo, A, Lee, DJ, Schwab, D, Eby, Y, Tokino, K, van der Riet, P, Blaugrund, JE & Sidransky, D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415–416
Cairns, P, Polascik, TJ, Eby, Y, Tokino, K, Califano, J, Merlo, A, Mao, L, Herath, J, Jenkins, R, Westra, W, Rutter, JL, Buckler, A, Gabrielson, E, Tockman, M, Cho, KR, Hedrick, L, Bova, GS, Isaacs, W, Koch, W, Schwab, D & Sidransky, D (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210–212
Caldas, C, Hahn, SA, Costa, LT, Redston, MS, Schutte, M, Seymour, AB, Weinstein, CL, Hruban, RH, Yeo, CJ & Kern, SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27–32
Califano, J, van der Riet, P, Westra, W, Nawroz, H, Clayman, G, Piantadosi, S, Corio, R, Lee, D, Greenberg, B, Koch, W & Sidransky, D (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488–2492
Chin, L, Pomerantz, J & DePinho, RA (1998) The INK4a/ARF tumor supressor: one gene, two products, two pathways. Trends Biochem. Sci 23: 291–296
El-Naggar, AK, Lai, S, Clayman, G, Lee, JK, Luna, MA, Goepfert, H & Batsakis, JG (1997) Methylation, a major mechanism of p16/cdkn2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 151: 1767–1774
Farrell, WE, Simpson, DJ, Bicknell, JE, Talbot, AJ, Bates, AS & Clayton, RN (1997) Chromosome 9p deletions in invasive and noninvasive non-functional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 57: 2703–2709
Flores, JF, Walker, GJ, Glendening, JM, Haluska, FG, Castresana, JS, Rubio, MP, Pastorfide, GC, Boyer, LA, Kao, WH, Bulyk, ML, Barnhill, RL, Hayward, NK, Housman, DE & Fountain, JW (1996) Loss of p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56: 5023–5032
Fueyo, J, Gomez-Manzano, C, Bruner, JM, Saito, Y, Zhang, B, Zhang, W, Levin, VA, Yung, WA & Kyritsis, AP (1996) Hypermethylation of the CpG island of p16/cdkn2 correlates with gene inactivation in gliomas. Oncogene 13: 1615–1619
Furlong, RA, Lyall, JE, Lush, MJ, Affara, NA & Ferguson-Smith, MA (1992) Four dinucleotide repeat polymorphisms on chromosome 9 (D9S143-D9S146). Hum Mol Genet 1: 447
Gallo, O, Santucci, M & Franchi, A (1997) Cumulative prognostic value of p16/cdkn2 and p53 oncoprotein expression in premalignant laryngeal lesions. J Natl Cancer Inst 89: 1161–1163
Gonzáles, MV, Pello, MF, López-Larrea, C, Suárez, C, Menéndez, MJ & Coto, E (1997) Deletion and methylation of the tumour supressor gene p16/cdkn2 in primary head and neck squamous cell carcinoma. J Clin Pathol 50: 509–512
Gyapay, G, Morissete, J, Vignal, A, Dib, C, Fizames, C, Millasseau, P, Marc, S, Bernardi, G, Lanttrop, M & Weissenbach, J (1994) The 1993–1994 généthon human genetic linkage map. Nat Genet 7: 246–339
Herman, JG, Merlo, A, Mao, L, Lapidus, RG, Issa, JPJ, Davidson, NE, Sidransky, D & Baylin, SB (1995) Inactivation of the cdkn2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525–4530
Hunter, T & Pines, J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573–582
Hussussian, CJ, Struewing, JP, Goldstein, AM, Higgins, PAT, Ally, DS, Sheahan, MD, Clark, WH, Tucker, MA & Dracopoli, NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8: 15–21
Jares, P, Fernández, PL, Nadal, A, Cazorla, M, Hernández, L, Pinyol, M, Hernández, S, Traserra, J, Cardesa, A & Campo, E (1997) p16MTS1/CDK41 mutations and concomitant loss of heterozygosity at 9p21–23 are frequent events in squamous cell carcinoma of the larynx. Oncogene 15: 1445–1453
Jarrard, DF, Bova, GS, Ewing, CM, Pin, SS, Nguyen, SH, Baylin, SB, Cairns, P, Sidransky, D, Herman, JG & Isaacs, WB (1997) Deletional, mutational and methylation analyses of CDKN2 (p16/MST1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19: 90–96
Kamb, A, Gruis, NA, Weaver-Feldhaus, J, Liu, Q, Harshman, K, Tavtigian, SV, Stockert, E, Day, III RS, Johnson, BE & Skolnick, MH (1994a) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440
Kamb, A, Shattuck-Eidens, D, Eeles, R, Liu, Q, Gruis, NA, Ding, W, Hussey, C, Tran, T, Miki, Y, Weaver-Feldhaus, J, McClure, M, Aitken, JF, Anderson, DE, Bergman, W, Frants, R, Goldgar, DE, Green, A, MacLennan, R, Martin, NG, Meyer, LJ, Youl, P, Zone, JJ, Skolnick, MH & Cannon-Albright, LA (1994b) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 22–26
Kamijo, T, Weber, JD, Zambetti, G, Zindy, F, Roussel, MF & Sherr, CJ (1998) Functional and physical interactions of the ARF tumor supressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292–8297
Kaplan, EL & Meier, P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kim, SK, Ro, JY, Kemp, BL, Lee, JS, Kwon, TJ, Fong, KM, Sekido, Y, Minna, JD, Hong, WK & Mao, L (1997) Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 57: 400–403
Koh, J, Enders, GH, Dynlacht, BD & Harlow, E (1995) Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506–510
Kwiatkowski, DJ & Diaz, MO (1993) Dinucleotide repeat polymorphism at IFNA locus (9p22). Hum Mol Genet 1: 658
Liggett, WH Jr, Sewell, DA, Rocco, J, Ahrendt, SA, Koch, W & Sidransky, D (1996) p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56: 4119–4123
Lo, KW, Cheung, ST, Leung, SF, van Hasselt, A, Tsang, YS, Mak, KF, Shung, YF, Woo, JKS, Lee, JCK & Huang, DP (1996) Hypermethylation of p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721–2725
Lydiatt, WM, Murty, VVVS, Davidson, BJ, Xu, L, Dyomina, K, Sacks, PG, Schantz, SP & Chaganti, RSK (1995) Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes Chrom & Cancer 13: 94–98
Maesawa, C, Tamura, G, Nishizuka, S, Ogasawara, S, Ishida, K, Terashima, M, Sakata, K, Sato, N, Saito, K & Satodate, R (1996) Inactivation of the CDKN2 gene by homozygous deletion and de Novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 56: 3875–3878
Merlo, A, Herman, JG, Mao, L, Lee, DJ, Gabrielson, E, Burger, PC, Baylin, SB & Sidransky, D (1995) 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686–692
Mori, T, Miura, K, Aoki, T, Nishihira, T, Mori, S & Nakamura, Y (1994) Frequent somatic mutation of MTS1/CDKN4I (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396–3397
Nagai, MA, Marques, LA, Torloni, H & Brentani, MM (1993) Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50: 412–417
Nawroz, H, van der Riet, P, Hruban, RH, Koch, W, Ruppert, JM & Sidransky, D (1994) Allelotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152–1155
Ng, MHL, Chung, YF, Lo, KW, Wickham, NWR, Lee, JCK & Huang, DP (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89: 2500–2506
Nobori, T, Miura, K, Wu, DJ, Lois, A, Takabayashi, K & Carson, DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756
Okamoto, A, Demetrick, DJ, Spillare, EA, Hagiwara, K, Hussain, SP, Bennett, WP, Forrester, K, Gerwin, B, Serrano, M, Beach, DH & Harris, CC (1994) Mutations and altered expression of p16 in human cancer. Proc Natl Acad Sci USA 91: 11045–11049
Papadimitrakopoulou, V, Izzo, J, Lippman, SM, Lee, JS, Fan, YH, Clayman, G, Ro, JY, Hittelman, WN, Lotan, R, Hong, WK & Mao, L (1997) Frequent inctivation p16INK4a in oral premalignant lesions. Oncogene 14: 1799–1803
Pollock, PM, Pearson, JV & Hayward, NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 15: 77–88
Puig, S, Ruiz, A, Lázaro, C, Castel, T, Lynch, M, Palou, J, Vilalta, A, Weissenbach, J, Mascaro, JM & Estivill, X (1995) Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside de p16 (CDKN2) gene. Am J Hum Genet 57: 395–402
Quelle, DE, Cheng, M, Ashmun, RA & Sherr, CJ (1997) Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94: 669–673
Quelle, DE, Zindy, F, Ashmun, RA & Sherr, CJ (1995) Alternative reading frames of the INK4a tumor supressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000
Ranade, K, Hussussian, CJ, Sikorski, RS, Varmus, HE, Goldstein, AM, Tucker, MA, Serrano, M, Hannon, GJ, Beach, D & Dracopoli, NC (1995) Mutations associated with familial melanoma impair p16 (INK4) function. Nat Genet 10: 114–116
Reed, AL, Califano, J, Cairns, P, Westra, WH, Jones, RM, Koch, W, Ahrendt, S, Eby, Y, Sewell, D, Nawroz, H, Bartek, J & Sidransky, D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630–3633
Serrano, M, Hannon, GJ & Beach, D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707
Serrano, M, Lee, H, Chin, L, Cordon-Cardo, C, Beach, D & DePinho, RA (1996) Role of INK4a locus in tumor supression and cell mortality. Cell 85: 27–37
Stone, S, Jiang, P, Dayananth, P, Tavtigian, SW, Katcher, H, Parry, D, Peters, G & Kamb, A (1995) Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55: 2988–2994
Sun, Y, Hildesheim, A, Lanier, AE, Cao, Y, Yao, KT, Raab-Traub, N & Yang, CS (1995) No point mutation but decreased expression of p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 10: 785–788
Tam, SW, Shay, JW & Pagano, M (1994) Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res 54: 5816–5820
van der Reit, P, Nawroz, H, Hruban, RH, Corio, R, Tokino, K, Koch, W & Sidransky, D (1994) Frequent loss of chromosome 9p21–22 early in head and neck progression. Cancer Res 54: 1156–1158
Williamson, MP, Elder, PA, Shaw, ME, Devlin, J & Knowles, MA (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569–1577
Wong, DJ, Barret, MT, Stöger, R, Emond, MJ & Reid, BJ (1997) p16INK4a promoter is hypermethylated at high frequency in esophageal adenocarcinomas. Cancer Res 57: 2619–2622
Yeundall, WA & Jakus, J (1995) Cyclin kinase inhibitors add a new dimension to cell cycle control. Eur J Cancer B Oral Oncol 31B: 291–298
Zhang, SY, Klein-Szanto, AJP, Sauter, ER, Shafarenko, M, Mitsunaga, S, Nobori, T, Carson, DA, Ridge, JA & Goodrow, TL (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumours of the head and neck. Cancer Res 54: 5050–5053
Author information
Authors and Affiliations
Additional information
Correspondence to:MA Nagai
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Miracca, E., Kowalski, L. & Nagai, M. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 81, 677–683 (1999). https://doi.org/10.1038/sj.bjc.6690747
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690747
Keywords
This article is cited by
-
Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy
Scientific Reports (2021)
-
Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine
EPMA Journal (2019)
-
Molecular Characterization of Head and Neck Cancer
Molecular Diagnosis & Therapy (2012)
-
Role of DNA methylation in head and neck cancer
Clinical Epigenetics (2011)
-
Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients
Molecular Biology Reports (2010)